The NOBLE study is a Phase-2 multi-center, randomized, double blind, placebo-controlled, parallel group study that will explore the potential of the investigational drug T-817MA, a neuroprotectant agent designed to protect against neuron loss. Neuroprotectants are used for many central nervous system disorders including stroke and Parkinson’s disease. The study will enroll 450 people with mild-to-moderate AD at many research sites across the United States. The duration of treatment is about 14 months.
The medical research community, through this study and others, is dedicated to finding hope for AD sufferers and leaving no one behind. The NOBLE study is sponsored by Toyama Chemical Co., Ltd, FUJIFILM Group, and is being conducted by the Alzheimer’s Disease Cooperative Study (ADCS). For additional information, visit: www.adcs.org
Toyama Chemical - The NOBLE Study at Rush University Medical Center is a trial studies located in Chicago, IL.